Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection

Current HIV Research

Volumn 5, Issue 3, 2007, Pages 355-360

  Jongwutiwes, Ubonvan ^a   Kiertiburanakul, Sasisopin ^a   Sungkanuparph, Somnuek ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; Cryptococcosis; HIV; Relapse; Survival

Indexed keywords

AMPHOTERICIN B; ANTIRETROVIRUS AGENT; EFAVIRENZ; FLUCONAZOLE; ITRACONAZOLE; NEVIRAPINE; NYSTATIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CRYPTOCOCCOSIS; DEMOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROPORTIONAL HAZARDS MODEL; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; SURVIVAL RATE; THERAPY EFFECT;

ADULT; ANTI-HIV AGENTS; ANTIFUNGAL AGENTS; COHORT STUDIES; CRYPTOCOCCOSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 34249016058     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207780636551     Document Type: Review

References (24)

1. Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE, Kaplan JE; HIV Medicine Association of the Infectious Diseases Society of America (2004). Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases. 39:609-629.
2. Antinori S, Galimberti L, Magni C, Casella A, Vago L, Mainini F, Piazza M, Nebuloni M, Fasan M, Bonaccorso C, Vigevani GM, Cargnel A, Moroni M, Ridolfo A. (2001). Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters, and autopsy findings. European Journal of Clinical Microbiology & Infectious Diseases. 20:711-717.
3. Chan CW, Cheng LS, Chan WK and Wong KH. (2005). Highly active antiretroviral therapy per se decreased mortality and morbidity of advanced human immunodeficiency virus disease in Hong Kong. Chinese Medical Journal. 118:1338-1345.
4. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, Lalloo D, Whitworth JA, Gilks CF. (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 16:1031-1038.
5. Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, Wheat LJ, Nyangweso PM, Yiannoutsos CT, Schnizlein-Bick CT, Owens S, Aberg JA; AIDS Clinical Trials Group A5038 Study Group. (2004). Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical Infectious Diseases. 38:1485-1489.
6. Heyderman RS, Gangaidzo IT, Hakim JG, Mielke J, Taziwa A, Musvaire P, Robertson VJ, Mason PR. (1998). Cryptococcal meningitis in human immunodeficiency virus-infected patients in Harare, Zimbabwe. Clinical Infectious Diseases. 26:284-289.
7. Jean SS, Fang CT, Shau WY, Chen YC, Chang SC, Hsueh PR, Hung CC, Luh KT. (2002). Cryptococcaemia: clinical features and prognostic factors. QJM. 95:511-518.
8. Khanna N, Chandramuki A, Desai A and Ravi V. (1996). Cryptococcal infections of the central nervous system: an analysis of predisposing factors, laboratory findings and outcome in patients from South India with special reference to HIV infection. Journal of Medical Microbiology. 45:376-379.
9. Mayanja-Kizza H, Oishi K, Mitarai S, Yamashita H, Nalongo K, Watanabe K, Izumi T, Ococi-Jungala, Augustine K, Mugerwa R, Nagatake T, Matsumoto K. (1998). Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clinical Infectious Diseases. 26:1362-1366.
10. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN, Lundgren JD; EuroSIDA study group. (2003). Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 362:22-29.
11. Moore RD, Chaisson RE. (1996). Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Annal of Internal Medicine. 124:633-642.
12. Moosa MY, Coovadia YM. (1997). Cryptococcal meningitis in Durban, South Africa: a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients. Clinical Infectious Diseases. 24:131-134.
13. Morris A, Wachter RM, Luce J, Turner J and Huang L. (2003). Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS. 17:73-80.
14. Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, Zumla A. (2001). Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgraduate Medical Journal. 77:769-773.
15. Pasqualotto AC, Bittencourt Severo C, de Mattos Oliveira F and Severo LC. (2004). Cryptococcemia. An analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent. Revista Iberoamericana de Micologia. 21:143-146.
16. Powderly WG. (1996). Recent advances in the management of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases. 22(Suppl 2):S119-S123.
17. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, Geretti AM, Johnson M, Leen C, Peters B, Pozniak A, Ross J, Walsh J, Wilkins E, Youle M; Writing Committee, British HIV Association. (2006). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Medicine. 7:487-503.
18. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, Fessel WJ, Moskovitz BL, Wiesinger B, Cosmatos D, Riser L, Thomas C, Hafner R, Dismukes WE. (1999). A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clinical Infectious Diseases. 28:291-296.
19. Salzberger B, Hartmann P, Hanses F, Uyanik B, Cornely OA, Wohrmann A, Fatkenheuer G. (2005). Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy. Infection. 33:345-349.
20. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RH, Patterson TF, Pottage JC Jr, Simberkoff MS, Wolf J, Meyer RD, Gupta R, Lee LW, Gordon DS. (1996). Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clinical Infectious Diseases. 22:315-321.
21. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M; Swiss HIV Cohort Study. (2005). Longterm effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 366:378-384.
22. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE. (1997). Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. New England Journal of Medicine. 337:15-21.
23. Vibhagool A, Sungkanuparph S, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C, Ingsathit A. (2003). Discontinuation of secondary prophylaxis for cryptococcal meningitis in HIV-infected patients treated with HAART: A prospective multicenter randomized study. Clinical Infectious Diseases. 36:1329-1331.
24. Vidal JE, Hernandez AV, de Oliveira AC, Dauar RF, Barbosa SP, Jr. and Focaccia R. (2005). Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care and STDs. 19:626-634.